TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens

MLA

Saomi Murai, et al. “TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-Spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens.” Molecular Cancer Therapeutics, vol. 11, Mar. 2012, pp. 700–09. EBSCOhost, https://doi.org/10.1158/1535-7163.mct-11-0762.

APA

Saomi Murai, Isao Kaieda, Tomohiro Kawamoto, Zhe Nie, Maki Hasegawa, Takashi Sato, Erik Kupperman, Keisuke Kuida, Takashi Ichikawa, Lilly Zhang, Koki Hikami, Hitoshi Miyashita, Sheldon X. Cao, Yuichi Hikichi, Kouhei Honda, Johnny Yang, & Noriko Uchiyama. (2012). TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens. Molecular Cancer Therapeutics, 11, 700–709. https://doi.org/10.1158/1535-7163.mct-11-0762

Chicago

Saomi Murai, Isao Kaieda, Tomohiro Kawamoto, Zhe Nie, Maki Hasegawa, Takashi Sato, Erik Kupperman, et al. 2012. “TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-Spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens.” Molecular Cancer Therapeutics 11 (March): 700–709. doi:10.1158/1535-7163.mct-11-0762.